Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Growth 2025-2031
The global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) market size is predicted to grow from US$ 355 million in 2025 to US$ 516 million in 2031; it is expected to grow at a CAGR of 6.4% from 2025 to 2031.
A nucleoside antiviral active pharmaceutical ingredient (API) is a chemically synthesized or biologically derived compound used as the key component in antiviral medications. These APIs mimic natural nucleosides and interfere with viral DNA or RNA replication, effectively inhibiting virus proliferation. Common examples include acyclovir, zidovudine, lamivudine, and entecavir.
United States market for Nucleoside Antiviral Active Pharmaceutical Ingredient (API) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Nucleoside Antiviral Active Pharmaceutical Ingredient (API) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Nucleoside Antiviral Active Pharmaceutical Ingredient (API) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Nucleoside Antiviral Active Pharmaceutical Ingredient (API) players cover Fuxiang Pharmaceuticals, Zhejiang Zhebei Pharmaceuticals, Hongyuan Pharmaceuticals, Xinxiang Pharmaceuticals, Hubei Yitai Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Industry Forecast” looks at past sales and reviews total world Nucleoside Antiviral Active Pharmaceutical Ingredient (API) sales in 2024, providing a comprehensive analysis by region and market sector of projected Nucleoside Antiviral Active Pharmaceutical Ingredient (API) sales for 2025 through 2031. With Nucleoside Antiviral Active Pharmaceutical Ingredient (API) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nucleoside Antiviral Active Pharmaceutical Ingredient (API) industry.
This Insight Report provides a comprehensive analysis of the global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nucleoside Antiviral Active Pharmaceutical Ingredient (API) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nucleoside Antiviral Active Pharmaceutical Ingredient (API) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nucleoside Antiviral Active Pharmaceutical Ingredient (API).
This report presents a comprehensive overview, market shares, and growth opportunities of Nucleoside Antiviral Active Pharmaceutical Ingredient (API) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) market?
What factors are driving Nucleoside Antiviral Active Pharmaceutical Ingredient (API) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Nucleoside Antiviral Active Pharmaceutical Ingredient (API) market opportunities vary by end market size?
How does Nucleoside Antiviral Active Pharmaceutical Ingredient (API) break out by Type, by Application?
A nucleoside antiviral active pharmaceutical ingredient (API) is a chemically synthesized or biologically derived compound used as the key component in antiviral medications. These APIs mimic natural nucleosides and interfere with viral DNA or RNA replication, effectively inhibiting virus proliferation. Common examples include acyclovir, zidovudine, lamivudine, and entecavir.
United States market for Nucleoside Antiviral Active Pharmaceutical Ingredient (API) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Nucleoside Antiviral Active Pharmaceutical Ingredient (API) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Nucleoside Antiviral Active Pharmaceutical Ingredient (API) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Nucleoside Antiviral Active Pharmaceutical Ingredient (API) players cover Fuxiang Pharmaceuticals, Zhejiang Zhebei Pharmaceuticals, Hongyuan Pharmaceuticals, Xinxiang Pharmaceuticals, Hubei Yitai Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Industry Forecast” looks at past sales and reviews total world Nucleoside Antiviral Active Pharmaceutical Ingredient (API) sales in 2024, providing a comprehensive analysis by region and market sector of projected Nucleoside Antiviral Active Pharmaceutical Ingredient (API) sales for 2025 through 2031. With Nucleoside Antiviral Active Pharmaceutical Ingredient (API) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nucleoside Antiviral Active Pharmaceutical Ingredient (API) industry.
This Insight Report provides a comprehensive analysis of the global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nucleoside Antiviral Active Pharmaceutical Ingredient (API) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nucleoside Antiviral Active Pharmaceutical Ingredient (API) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nucleoside Antiviral Active Pharmaceutical Ingredient (API).
This report presents a comprehensive overview, market shares, and growth opportunities of Nucleoside Antiviral Active Pharmaceutical Ingredient (API) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Acyclovir API
- Zidovudine API
- Entecavir API
- Sofosbuvir API
- Other
- Pharmaceuticals
- Scientific Research
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Fuxiang Pharmaceuticals
- Zhejiang Zhebei Pharmaceuticals
- Hongyuan Pharmaceuticals
- Xinxiang Pharmaceuticals
- Hubei Yitai Pharmaceuticals
- Chongqing Qingyang Pharmaceuticals
- Zhejiang Chengyi Pharmaceuticals
- Tianjin Junan Biopharmaceuticals
- Shanghai Pharmaceuticals Kangli
- Zhejiang Chetou Pharmaceuticals
- Mangalam
- Adrovent Pharma
- Vinuthana
- Atom pharma
- Clearsynth
- Mylan
- Hetero Drugs
- Cipla
- Nortec Quimica
- Globe Quimica Ltda
- Octavius Pharma
- Apotex Pharmachem
What is the 10-year outlook for the global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) market?
What factors are driving Nucleoside Antiviral Active Pharmaceutical Ingredient (API) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Nucleoside Antiviral Active Pharmaceutical Ingredient (API) market opportunities vary by end market size?
How does Nucleoside Antiviral Active Pharmaceutical Ingredient (API) break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Nucleoside Antiviral Active Pharmaceutical Ingredient (API) by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Nucleoside Antiviral Active Pharmaceutical Ingredient (API) by Country/Region, 2020, 2024 & 2031
2.2 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Segment by Type
2.2.1 Acyclovir API
2.2.2 Zidovudine API
2.2.3 Entecavir API
2.2.4 Sofosbuvir API
2.2.5 Other
2.3 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type
2.3.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Type (2020-2025)
2.3.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue and Market Share by Type (2020-2025)
2.3.3 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Price by Type (2020-2025)
2.4 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Segment by Application
2.4.1 Pharmaceuticals
2.4.2 Scientific Research
2.5 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application
2.5.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Market Share by Application (2020-2025)
2.5.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue and Market Share by Application (2020-2025)
2.5.3 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Breakdown Data by Company
3.1.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Sales by Company (2020-2025)
3.1.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Company (2020-2025)
3.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Revenue by Company (2020-2025)
3.2.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Company (2020-2025)
3.2.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Company (2020-2025)
3.3 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Price by Company
3.4 Key Manufacturers Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Location Distribution
3.4.2 Players Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NUCLEOSIDE ANTIVIRAL ACTIVE PHARMACEUTICAL INGREDIENT (API) BY GEOGRAPHIC REGION
4.1 World Historic Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Size by Geographic Region (2020-2025)
4.1.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Size by Country/Region (2020-2025)
4.2.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Sales by Country/Region (2020-2025)
4.2.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Revenue by Country/Region (2020-2025)
4.3 Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Growth
4.4 APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Growth
4.5 Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Growth
4.6 Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Growth
5 AMERICAS
5.1 Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country
5.1.1 Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025)
5.1.2 Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2025)
5.2 Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025)
5.3 Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Region
6.1.1 APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Region (2020-2025)
6.1.2 APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Region (2020-2025)
6.2 APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025)
6.3 APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) by Country
7.1.1 Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025)
7.1.2 Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2025)
7.2 Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025)
7.3 Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) by Country
8.1.1 Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025)
8.1.2 Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2025)
8.2 Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025)
8.3 Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
10.3 Manufacturing Process Analysis of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
10.4 Industry Chain Structure of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Distributors
11.3 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Customer
12 WORLD FORECAST REVIEW FOR NUCLEOSIDE ANTIVIRAL ACTIVE PHARMACEUTICAL INGREDIENT (API) BY GEOGRAPHIC REGION
12.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Size Forecast by Region
12.1.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Forecast by Region (2026-2031)
12.1.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Forecast by Type (2026-2031)
12.7 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Fuxiang Pharmaceuticals
13.1.1 Fuxiang Pharmaceuticals Company Information
13.1.2 Fuxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.1.3 Fuxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Fuxiang Pharmaceuticals Main Business Overview
13.1.5 Fuxiang Pharmaceuticals Latest Developments
13.2 Zhejiang Zhebei Pharmaceuticals
13.2.1 Zhejiang Zhebei Pharmaceuticals Company Information
13.2.2 Zhejiang Zhebei Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.2.3 Zhejiang Zhebei Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Zhejiang Zhebei Pharmaceuticals Main Business Overview
13.2.5 Zhejiang Zhebei Pharmaceuticals Latest Developments
13.3 Hongyuan Pharmaceuticals
13.3.1 Hongyuan Pharmaceuticals Company Information
13.3.2 Hongyuan Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.3.3 Hongyuan Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Hongyuan Pharmaceuticals Main Business Overview
13.3.5 Hongyuan Pharmaceuticals Latest Developments
13.4 Xinxiang Pharmaceuticals
13.4.1 Xinxiang Pharmaceuticals Company Information
13.4.2 Xinxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.4.3 Xinxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Xinxiang Pharmaceuticals Main Business Overview
13.4.5 Xinxiang Pharmaceuticals Latest Developments
13.5 Hubei Yitai Pharmaceuticals
13.5.1 Hubei Yitai Pharmaceuticals Company Information
13.5.2 Hubei Yitai Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.5.3 Hubei Yitai Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Hubei Yitai Pharmaceuticals Main Business Overview
13.5.5 Hubei Yitai Pharmaceuticals Latest Developments
13.6 Chongqing Qingyang Pharmaceuticals
13.6.1 Chongqing Qingyang Pharmaceuticals Company Information
13.6.2 Chongqing Qingyang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.6.3 Chongqing Qingyang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Chongqing Qingyang Pharmaceuticals Main Business Overview
13.6.5 Chongqing Qingyang Pharmaceuticals Latest Developments
13.7 Zhejiang Chengyi Pharmaceuticals
13.7.1 Zhejiang Chengyi Pharmaceuticals Company Information
13.7.2 Zhejiang Chengyi Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.7.3 Zhejiang Chengyi Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Zhejiang Chengyi Pharmaceuticals Main Business Overview
13.7.5 Zhejiang Chengyi Pharmaceuticals Latest Developments
13.8 Tianjin Junan Biopharmaceuticals
13.8.1 Tianjin Junan Biopharmaceuticals Company Information
13.8.2 Tianjin Junan Biopharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.8.3 Tianjin Junan Biopharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Tianjin Junan Biopharmaceuticals Main Business Overview
13.8.5 Tianjin Junan Biopharmaceuticals Latest Developments
13.9 Shanghai Pharmaceuticals Kangli
13.9.1 Shanghai Pharmaceuticals Kangli Company Information
13.9.2 Shanghai Pharmaceuticals Kangli Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.9.3 Shanghai Pharmaceuticals Kangli Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Shanghai Pharmaceuticals Kangli Main Business Overview
13.9.5 Shanghai Pharmaceuticals Kangli Latest Developments
13.10 Zhejiang Chetou Pharmaceuticals
13.10.1 Zhejiang Chetou Pharmaceuticals Company Information
13.10.2 Zhejiang Chetou Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.10.3 Zhejiang Chetou Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Zhejiang Chetou Pharmaceuticals Main Business Overview
13.10.5 Zhejiang Chetou Pharmaceuticals Latest Developments
13.11 Mangalam
13.11.1 Mangalam Company Information
13.11.2 Mangalam Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.11.3 Mangalam Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Mangalam Main Business Overview
13.11.5 Mangalam Latest Developments
13.12 Adrovent Pharma
13.12.1 Adrovent Pharma Company Information
13.12.2 Adrovent Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.12.3 Adrovent Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Adrovent Pharma Main Business Overview
13.12.5 Adrovent Pharma Latest Developments
13.13 Vinuthana
13.13.1 Vinuthana Company Information
13.13.2 Vinuthana Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.13.3 Vinuthana Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Vinuthana Main Business Overview
13.13.5 Vinuthana Latest Developments
13.14 Atom pharma
13.14.1 Atom pharma Company Information
13.14.2 Atom pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.14.3 Atom pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Atom pharma Main Business Overview
13.14.5 Atom pharma Latest Developments
13.15 Clearsynth
13.15.1 Clearsynth Company Information
13.15.2 Clearsynth Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.15.3 Clearsynth Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Clearsynth Main Business Overview
13.15.5 Clearsynth Latest Developments
13.16 Mylan
13.16.1 Mylan Company Information
13.16.2 Mylan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.16.3 Mylan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Mylan Main Business Overview
13.16.5 Mylan Latest Developments
13.17 Hetero Drugs
13.17.1 Hetero Drugs Company Information
13.17.2 Hetero Drugs Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.17.3 Hetero Drugs Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Hetero Drugs Main Business Overview
13.17.5 Hetero Drugs Latest Developments
13.18 Cipla
13.18.1 Cipla Company Information
13.18.2 Cipla Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.18.3 Cipla Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Cipla Main Business Overview
13.18.5 Cipla Latest Developments
13.19 Nortec Quimica
13.19.1 Nortec Quimica Company Information
13.19.2 Nortec Quimica Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.19.3 Nortec Quimica Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 Nortec Quimica Main Business Overview
13.19.5 Nortec Quimica Latest Developments
13.20 Globe Quimica Ltda
13.20.1 Globe Quimica Ltda Company Information
13.20.2 Globe Quimica Ltda Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.20.3 Globe Quimica Ltda Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.20.4 Globe Quimica Ltda Main Business Overview
13.20.5 Globe Quimica Ltda Latest Developments
13.21 Octavius Pharma
13.21.1 Octavius Pharma Company Information
13.21.2 Octavius Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.21.3 Octavius Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.21.4 Octavius Pharma Main Business Overview
13.21.5 Octavius Pharma Latest Developments
13.22 Apotex Pharmachem
13.22.1 Apotex Pharmachem Company Information
13.22.2 Apotex Pharmachem Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.22.3 Apotex Pharmachem Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.22.4 Apotex Pharmachem Main Business Overview
13.22.5 Apotex Pharmachem Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Nucleoside Antiviral Active Pharmaceutical Ingredient (API) by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Nucleoside Antiviral Active Pharmaceutical Ingredient (API) by Country/Region, 2020, 2024 & 2031
2.2 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Segment by Type
2.2.1 Acyclovir API
2.2.2 Zidovudine API
2.2.3 Entecavir API
2.2.4 Sofosbuvir API
2.2.5 Other
2.3 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type
2.3.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Type (2020-2025)
2.3.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue and Market Share by Type (2020-2025)
2.3.3 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Price by Type (2020-2025)
2.4 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Segment by Application
2.4.1 Pharmaceuticals
2.4.2 Scientific Research
2.5 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application
2.5.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Market Share by Application (2020-2025)
2.5.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue and Market Share by Application (2020-2025)
2.5.3 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Breakdown Data by Company
3.1.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Sales by Company (2020-2025)
3.1.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Company (2020-2025)
3.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Revenue by Company (2020-2025)
3.2.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Company (2020-2025)
3.2.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Company (2020-2025)
3.3 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Price by Company
3.4 Key Manufacturers Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Location Distribution
3.4.2 Players Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NUCLEOSIDE ANTIVIRAL ACTIVE PHARMACEUTICAL INGREDIENT (API) BY GEOGRAPHIC REGION
4.1 World Historic Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Size by Geographic Region (2020-2025)
4.1.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Size by Country/Region (2020-2025)
4.2.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Sales by Country/Region (2020-2025)
4.2.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Revenue by Country/Region (2020-2025)
4.3 Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Growth
4.4 APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Growth
4.5 Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Growth
4.6 Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Growth
5 AMERICAS
5.1 Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country
5.1.1 Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025)
5.1.2 Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2025)
5.2 Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025)
5.3 Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Region
6.1.1 APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Region (2020-2025)
6.1.2 APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Region (2020-2025)
6.2 APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025)
6.3 APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) by Country
7.1.1 Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025)
7.1.2 Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2025)
7.2 Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025)
7.3 Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) by Country
8.1.1 Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025)
8.1.2 Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2025)
8.2 Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025)
8.3 Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
10.3 Manufacturing Process Analysis of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
10.4 Industry Chain Structure of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Distributors
11.3 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Customer
12 WORLD FORECAST REVIEW FOR NUCLEOSIDE ANTIVIRAL ACTIVE PHARMACEUTICAL INGREDIENT (API) BY GEOGRAPHIC REGION
12.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Size Forecast by Region
12.1.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Forecast by Region (2026-2031)
12.1.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Forecast by Type (2026-2031)
12.7 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Fuxiang Pharmaceuticals
13.1.1 Fuxiang Pharmaceuticals Company Information
13.1.2 Fuxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.1.3 Fuxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Fuxiang Pharmaceuticals Main Business Overview
13.1.5 Fuxiang Pharmaceuticals Latest Developments
13.2 Zhejiang Zhebei Pharmaceuticals
13.2.1 Zhejiang Zhebei Pharmaceuticals Company Information
13.2.2 Zhejiang Zhebei Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.2.3 Zhejiang Zhebei Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Zhejiang Zhebei Pharmaceuticals Main Business Overview
13.2.5 Zhejiang Zhebei Pharmaceuticals Latest Developments
13.3 Hongyuan Pharmaceuticals
13.3.1 Hongyuan Pharmaceuticals Company Information
13.3.2 Hongyuan Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.3.3 Hongyuan Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Hongyuan Pharmaceuticals Main Business Overview
13.3.5 Hongyuan Pharmaceuticals Latest Developments
13.4 Xinxiang Pharmaceuticals
13.4.1 Xinxiang Pharmaceuticals Company Information
13.4.2 Xinxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.4.3 Xinxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Xinxiang Pharmaceuticals Main Business Overview
13.4.5 Xinxiang Pharmaceuticals Latest Developments
13.5 Hubei Yitai Pharmaceuticals
13.5.1 Hubei Yitai Pharmaceuticals Company Information
13.5.2 Hubei Yitai Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.5.3 Hubei Yitai Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Hubei Yitai Pharmaceuticals Main Business Overview
13.5.5 Hubei Yitai Pharmaceuticals Latest Developments
13.6 Chongqing Qingyang Pharmaceuticals
13.6.1 Chongqing Qingyang Pharmaceuticals Company Information
13.6.2 Chongqing Qingyang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.6.3 Chongqing Qingyang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Chongqing Qingyang Pharmaceuticals Main Business Overview
13.6.5 Chongqing Qingyang Pharmaceuticals Latest Developments
13.7 Zhejiang Chengyi Pharmaceuticals
13.7.1 Zhejiang Chengyi Pharmaceuticals Company Information
13.7.2 Zhejiang Chengyi Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.7.3 Zhejiang Chengyi Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Zhejiang Chengyi Pharmaceuticals Main Business Overview
13.7.5 Zhejiang Chengyi Pharmaceuticals Latest Developments
13.8 Tianjin Junan Biopharmaceuticals
13.8.1 Tianjin Junan Biopharmaceuticals Company Information
13.8.2 Tianjin Junan Biopharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.8.3 Tianjin Junan Biopharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Tianjin Junan Biopharmaceuticals Main Business Overview
13.8.5 Tianjin Junan Biopharmaceuticals Latest Developments
13.9 Shanghai Pharmaceuticals Kangli
13.9.1 Shanghai Pharmaceuticals Kangli Company Information
13.9.2 Shanghai Pharmaceuticals Kangli Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.9.3 Shanghai Pharmaceuticals Kangli Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Shanghai Pharmaceuticals Kangli Main Business Overview
13.9.5 Shanghai Pharmaceuticals Kangli Latest Developments
13.10 Zhejiang Chetou Pharmaceuticals
13.10.1 Zhejiang Chetou Pharmaceuticals Company Information
13.10.2 Zhejiang Chetou Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.10.3 Zhejiang Chetou Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Zhejiang Chetou Pharmaceuticals Main Business Overview
13.10.5 Zhejiang Chetou Pharmaceuticals Latest Developments
13.11 Mangalam
13.11.1 Mangalam Company Information
13.11.2 Mangalam Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.11.3 Mangalam Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Mangalam Main Business Overview
13.11.5 Mangalam Latest Developments
13.12 Adrovent Pharma
13.12.1 Adrovent Pharma Company Information
13.12.2 Adrovent Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.12.3 Adrovent Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Adrovent Pharma Main Business Overview
13.12.5 Adrovent Pharma Latest Developments
13.13 Vinuthana
13.13.1 Vinuthana Company Information
13.13.2 Vinuthana Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.13.3 Vinuthana Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Vinuthana Main Business Overview
13.13.5 Vinuthana Latest Developments
13.14 Atom pharma
13.14.1 Atom pharma Company Information
13.14.2 Atom pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.14.3 Atom pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Atom pharma Main Business Overview
13.14.5 Atom pharma Latest Developments
13.15 Clearsynth
13.15.1 Clearsynth Company Information
13.15.2 Clearsynth Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.15.3 Clearsynth Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Clearsynth Main Business Overview
13.15.5 Clearsynth Latest Developments
13.16 Mylan
13.16.1 Mylan Company Information
13.16.2 Mylan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.16.3 Mylan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Mylan Main Business Overview
13.16.5 Mylan Latest Developments
13.17 Hetero Drugs
13.17.1 Hetero Drugs Company Information
13.17.2 Hetero Drugs Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.17.3 Hetero Drugs Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Hetero Drugs Main Business Overview
13.17.5 Hetero Drugs Latest Developments
13.18 Cipla
13.18.1 Cipla Company Information
13.18.2 Cipla Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.18.3 Cipla Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Cipla Main Business Overview
13.18.5 Cipla Latest Developments
13.19 Nortec Quimica
13.19.1 Nortec Quimica Company Information
13.19.2 Nortec Quimica Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.19.3 Nortec Quimica Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 Nortec Quimica Main Business Overview
13.19.5 Nortec Quimica Latest Developments
13.20 Globe Quimica Ltda
13.20.1 Globe Quimica Ltda Company Information
13.20.2 Globe Quimica Ltda Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.20.3 Globe Quimica Ltda Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.20.4 Globe Quimica Ltda Main Business Overview
13.20.5 Globe Quimica Ltda Latest Developments
13.21 Octavius Pharma
13.21.1 Octavius Pharma Company Information
13.21.2 Octavius Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.21.3 Octavius Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.21.4 Octavius Pharma Main Business Overview
13.21.5 Octavius Pharma Latest Developments
13.22 Apotex Pharmachem
13.22.1 Apotex Pharmachem Company Information
13.22.2 Apotex Pharmachem Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.22.3 Apotex Pharmachem Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.22.4 Apotex Pharmachem Main Business Overview
13.22.5 Apotex Pharmachem Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Acyclovir API
Table 4. Major Players of Zidovudine API
Table 5. Major Players of Entecavir API
Table 6. Major Players of Sofosbuvir API
Table 7. Major Players of Other
Table 8. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025) & (Tons)
Table 9. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Type (2020-2025)
Table 10. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Type (2020-2025) & ($ million)
Table 11. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Type (2020-2025)
Table 12. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Price by Type (2020-2025) & (US$/Ton)
Table 13. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale by Application (2020-2025) & (Tons)
Table 14. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Market Share by Application (2020-2025)
Table 15. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Application (2020-2025) & ($ million)
Table 16. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Application (2020-2025)
Table 17. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Price by Application (2020-2025) & (US$/Ton)
Table 18. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Company (2020-2025) & (Tons)
Table 19. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Company (2020-2025)
Table 20. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Company (2020-2025) & ($ millions)
Table 21. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Company (2020-2025)
Table 22. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Price by Company (2020-2025) & (US$/Ton)
Table 23. Key Manufacturers Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Producing Area Distribution and Sales Area
Table 24. Players Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Products Offered
Table 25. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Geographic Region (2020-2025) & (Tons)
Table 29. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share Geographic Region (2020-2025)
Table 30. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Geographic Region (2020-2025) & ($ millions)
Table 31. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Geographic Region (2020-2025)
Table 32. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country/Region (2020-2025) & (Tons)
Table 33. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country/Region (2020-2025)
Table 34. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country/Region (2020-2025) & ($ millions)
Table 35. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Country/Region (2020-2025)
Table 36. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025) & (Tons)
Table 37. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country (2020-2025)
Table 38. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2025) & ($ millions)
Table 39. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025) & (Tons)
Table 40. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025) & (Tons)
Table 41. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Region (2020-2025) & (Tons)
Table 42. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Region (2020-2025)
Table 43. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Region (2020-2025) & ($ millions)
Table 44. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025) & (Tons)
Table 45. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025) & (Tons)
Table 46. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025) & (Tons)
Table 47. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2025) & ($ millions)
Table 48. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025) & (Tons)
Table 49. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025) & (Tons)
Table 50. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025) & (Tons)
Table 51. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Country (2020-2025)
Table 52. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025) & (Tons)
Table 53. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025) & (Tons)
Table 54. Key Market Drivers & Growth Opportunities of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
Table 55. Key Market Challenges & Risks of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
Table 56. Key Industry Trends of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
Table 57. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Distributors List
Table 60. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Customer List
Table 61. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Forecast by Region (2026-2031) & (Tons)
Table 62. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Forecast by Region (2026-2031) & ($ millions)
Table 63. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Forecast by Country (2026-2031) & (Tons)
Table 64. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 65. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Forecast by Region (2026-2031) & (Tons)
Table 66. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 67. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Forecast by Country (2026-2031) & (Tons)
Table 68. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Forecast by Country (2026-2031) & (Tons)
Table 70. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Forecast by Country (2026-2031) & ($ millions)
Table 71. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Forecast by Type (2026-2031) & (Tons)
Table 72. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Forecast by Type (2026-2031) & ($ millions)
Table 73. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Forecast by Application (2026-2031) & (Tons)
Table 74. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Forecast by Application (2026-2031) & ($ millions)
Table 75. Fuxiang Pharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 76. Fuxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 77. Fuxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 78. Fuxiang Pharmaceuticals Main Business
Table 79. Fuxiang Pharmaceuticals Latest Developments
Table 80. Zhejiang Zhebei Pharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 81. Zhejiang Zhebei Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 82. Zhejiang Zhebei Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 83. Zhejiang Zhebei Pharmaceuticals Main Business
Table 84. Zhejiang Zhebei Pharmaceuticals Latest Developments
Table 85. Hongyuan Pharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 86. Hongyuan Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 87. Hongyuan Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 88. Hongyuan Pharmaceuticals Main Business
Table 89. Hongyuan Pharmaceuticals Latest Developments
Table 90. Xinxiang Pharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 91. Xinxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 92. Xinxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 93. Xinxiang Pharmaceuticals Main Business
Table 94. Xinxiang Pharmaceuticals Latest Developments
Table 95. Hubei Yitai Pharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 96. Hubei Yitai Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 97. Hubei Yitai Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 98. Hubei Yitai Pharmaceuticals Main Business
Table 99. Hubei Yitai Pharmaceuticals Latest Developments
Table 100. Chongqing Qingyang Pharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 101. Chongqing Qingyang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 102. Chongqing Qingyang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 103. Chongqing Qingyang Pharmaceuticals Main Business
Table 104. Chongqing Qingyang Pharmaceuticals Latest Developments
Table 105. Zhejiang Chengyi Pharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 106. Zhejiang Chengyi Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 107. Zhejiang Chengyi Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 108. Zhejiang Chengyi Pharmaceuticals Main Business
Table 109. Zhejiang Chengyi Pharmaceuticals Latest Developments
Table 110. Tianjin Junan Biopharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 111. Tianjin Junan Biopharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 112. Tianjin Junan Biopharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 113. Tianjin Junan Biopharmaceuticals Main Business
Table 114. Tianjin Junan Biopharmaceuticals Latest Developments
Table 115. Shanghai Pharmaceuticals Kangli Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 116. Shanghai Pharmaceuticals Kangli Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 117. Shanghai Pharmaceuticals Kangli Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 118. Shanghai Pharmaceuticals Kangli Main Business
Table 119. Shanghai Pharmaceuticals Kangli Latest Developments
Table 120. Zhejiang Chetou Pharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 121. Zhejiang Chetou Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 122. Zhejiang Chetou Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 123. Zhejiang Chetou Pharmaceuticals Main Business
Table 124. Zhejiang Chetou Pharmaceuticals Latest Developments
Table 125. Mangalam Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 126. Mangalam Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 127. Mangalam Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 128. Mangalam Main Business
Table 129. Mangalam Latest Developments
Table 130. Adrovent Pharma Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 131. Adrovent Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 132. Adrovent Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 133. Adrovent Pharma Main Business
Table 134. Adrovent Pharma Latest Developments
Table 135. Vinuthana Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 136. Vinuthana Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 137. Vinuthana Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 138. Vinuthana Main Business
Table 139. Vinuthana Latest Developments
Table 140. Atom pharma Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 141. Atom pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 142. Atom pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 143. Atom pharma Main Business
Table 144. Atom pharma Latest Developments
Table 145. Clearsynth Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 146. Clearsynth Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 147. Clearsynth Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 148. Clearsynth Main Business
Table 149. Clearsynth Latest Developments
Table 150. Mylan Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 151. Mylan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 152. Mylan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 153. Mylan Main Business
Table 154. Mylan Latest Developments
Table 155. Hetero Drugs Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 156. Hetero Drugs Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 157. Hetero Drugs Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 158. Hetero Drugs Main Business
Table 159. Hetero Drugs Latest Developments
Table 160. Cipla Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 161. Cipla Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 162. Cipla Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 163. Cipla Main Business
Table 164. Cipla Latest Developments
Table 165. Nortec Quimica Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 166. Nortec Quimica Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 167. Nortec Quimica Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 168. Nortec Quimica Main Business
Table 169. Nortec Quimica Latest Developments
Table 170. Globe Quimica Ltda Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 171. Globe Quimica Ltda Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 172. Globe Quimica Ltda Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 173. Globe Quimica Ltda Main Business
Table 174. Globe Quimica Ltda Latest Developments
Table 175. Octavius Pharma Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 176. Octavius Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 177. Octavius Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 178. Octavius Pharma Main Business
Table 179. Octavius Pharma Latest Developments
Table 180. Apotex Pharmachem Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 181. Apotex Pharmachem Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 182. Apotex Pharmachem Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 183. Apotex Pharmachem Main Business
Table 184. Apotex Pharmachem Latest Developments
Table 1. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Acyclovir API
Table 4. Major Players of Zidovudine API
Table 5. Major Players of Entecavir API
Table 6. Major Players of Sofosbuvir API
Table 7. Major Players of Other
Table 8. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025) & (Tons)
Table 9. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Type (2020-2025)
Table 10. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Type (2020-2025) & ($ million)
Table 11. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Type (2020-2025)
Table 12. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Price by Type (2020-2025) & (US$/Ton)
Table 13. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale by Application (2020-2025) & (Tons)
Table 14. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Market Share by Application (2020-2025)
Table 15. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Application (2020-2025) & ($ million)
Table 16. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Application (2020-2025)
Table 17. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Price by Application (2020-2025) & (US$/Ton)
Table 18. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Company (2020-2025) & (Tons)
Table 19. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Company (2020-2025)
Table 20. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Company (2020-2025) & ($ millions)
Table 21. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Company (2020-2025)
Table 22. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Price by Company (2020-2025) & (US$/Ton)
Table 23. Key Manufacturers Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Producing Area Distribution and Sales Area
Table 24. Players Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Products Offered
Table 25. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Geographic Region (2020-2025) & (Tons)
Table 29. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share Geographic Region (2020-2025)
Table 30. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Geographic Region (2020-2025) & ($ millions)
Table 31. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Geographic Region (2020-2025)
Table 32. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country/Region (2020-2025) & (Tons)
Table 33. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country/Region (2020-2025)
Table 34. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country/Region (2020-2025) & ($ millions)
Table 35. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Country/Region (2020-2025)
Table 36. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025) & (Tons)
Table 37. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country (2020-2025)
Table 38. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2025) & ($ millions)
Table 39. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025) & (Tons)
Table 40. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025) & (Tons)
Table 41. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Region (2020-2025) & (Tons)
Table 42. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Region (2020-2025)
Table 43. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Region (2020-2025) & ($ millions)
Table 44. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025) & (Tons)
Table 45. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025) & (Tons)
Table 46. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025) & (Tons)
Table 47. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2025) & ($ millions)
Table 48. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025) & (Tons)
Table 49. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025) & (Tons)
Table 50. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025) & (Tons)
Table 51. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Country (2020-2025)
Table 52. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025) & (Tons)
Table 53. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025) & (Tons)
Table 54. Key Market Drivers & Growth Opportunities of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
Table 55. Key Market Challenges & Risks of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
Table 56. Key Industry Trends of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
Table 57. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Distributors List
Table 60. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Customer List
Table 61. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Forecast by Region (2026-2031) & (Tons)
Table 62. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Forecast by Region (2026-2031) & ($ millions)
Table 63. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Forecast by Country (2026-2031) & (Tons)
Table 64. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 65. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Forecast by Region (2026-2031) & (Tons)
Table 66. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 67. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Forecast by Country (2026-2031) & (Tons)
Table 68. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Forecast by Country (2026-2031) & (Tons)
Table 70. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Forecast by Country (2026-2031) & ($ millions)
Table 71. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Forecast by Type (2026-2031) & (Tons)
Table 72. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Forecast by Type (2026-2031) & ($ millions)
Table 73. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Forecast by Application (2026-2031) & (Tons)
Table 74. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Forecast by Application (2026-2031) & ($ millions)
Table 75. Fuxiang Pharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 76. Fuxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 77. Fuxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 78. Fuxiang Pharmaceuticals Main Business
Table 79. Fuxiang Pharmaceuticals Latest Developments
Table 80. Zhejiang Zhebei Pharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 81. Zhejiang Zhebei Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 82. Zhejiang Zhebei Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 83. Zhejiang Zhebei Pharmaceuticals Main Business
Table 84. Zhejiang Zhebei Pharmaceuticals Latest Developments
Table 85. Hongyuan Pharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 86. Hongyuan Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 87. Hongyuan Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 88. Hongyuan Pharmaceuticals Main Business
Table 89. Hongyuan Pharmaceuticals Latest Developments
Table 90. Xinxiang Pharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 91. Xinxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 92. Xinxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 93. Xinxiang Pharmaceuticals Main Business
Table 94. Xinxiang Pharmaceuticals Latest Developments
Table 95. Hubei Yitai Pharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 96. Hubei Yitai Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 97. Hubei Yitai Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 98. Hubei Yitai Pharmaceuticals Main Business
Table 99. Hubei Yitai Pharmaceuticals Latest Developments
Table 100. Chongqing Qingyang Pharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 101. Chongqing Qingyang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 102. Chongqing Qingyang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 103. Chongqing Qingyang Pharmaceuticals Main Business
Table 104. Chongqing Qingyang Pharmaceuticals Latest Developments
Table 105. Zhejiang Chengyi Pharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 106. Zhejiang Chengyi Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 107. Zhejiang Chengyi Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 108. Zhejiang Chengyi Pharmaceuticals Main Business
Table 109. Zhejiang Chengyi Pharmaceuticals Latest Developments
Table 110. Tianjin Junan Biopharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 111. Tianjin Junan Biopharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 112. Tianjin Junan Biopharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 113. Tianjin Junan Biopharmaceuticals Main Business
Table 114. Tianjin Junan Biopharmaceuticals Latest Developments
Table 115. Shanghai Pharmaceuticals Kangli Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 116. Shanghai Pharmaceuticals Kangli Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 117. Shanghai Pharmaceuticals Kangli Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 118. Shanghai Pharmaceuticals Kangli Main Business
Table 119. Shanghai Pharmaceuticals Kangli Latest Developments
Table 120. Zhejiang Chetou Pharmaceuticals Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 121. Zhejiang Chetou Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 122. Zhejiang Chetou Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 123. Zhejiang Chetou Pharmaceuticals Main Business
Table 124. Zhejiang Chetou Pharmaceuticals Latest Developments
Table 125. Mangalam Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 126. Mangalam Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 127. Mangalam Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 128. Mangalam Main Business
Table 129. Mangalam Latest Developments
Table 130. Adrovent Pharma Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 131. Adrovent Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 132. Adrovent Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 133. Adrovent Pharma Main Business
Table 134. Adrovent Pharma Latest Developments
Table 135. Vinuthana Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 136. Vinuthana Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 137. Vinuthana Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 138. Vinuthana Main Business
Table 139. Vinuthana Latest Developments
Table 140. Atom pharma Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 141. Atom pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 142. Atom pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 143. Atom pharma Main Business
Table 144. Atom pharma Latest Developments
Table 145. Clearsynth Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 146. Clearsynth Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 147. Clearsynth Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 148. Clearsynth Main Business
Table 149. Clearsynth Latest Developments
Table 150. Mylan Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 151. Mylan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 152. Mylan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 153. Mylan Main Business
Table 154. Mylan Latest Developments
Table 155. Hetero Drugs Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 156. Hetero Drugs Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 157. Hetero Drugs Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 158. Hetero Drugs Main Business
Table 159. Hetero Drugs Latest Developments
Table 160. Cipla Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 161. Cipla Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 162. Cipla Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 163. Cipla Main Business
Table 164. Cipla Latest Developments
Table 165. Nortec Quimica Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 166. Nortec Quimica Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 167. Nortec Quimica Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 168. Nortec Quimica Main Business
Table 169. Nortec Quimica Latest Developments
Table 170. Globe Quimica Ltda Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 171. Globe Quimica Ltda Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 172. Globe Quimica Ltda Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 173. Globe Quimica Ltda Main Business
Table 174. Globe Quimica Ltda Latest Developments
Table 175. Octavius Pharma Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 176. Octavius Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 177. Octavius Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 178. Octavius Pharma Main Business
Table 179. Octavius Pharma Latest Developments
Table 180. Apotex Pharmachem Basic Information, Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Manufacturing Base, Sales Area and Its Competitors
Table 181. Apotex Pharmachem Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
Table 182. Apotex Pharmachem Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 183. Apotex Pharmachem Main Business
Table 184. Apotex Pharmachem Latest Developments
LIST OF FIGURES
Figure 1. Picture of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
Figure 2. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Growth Rate 2020-2031 (Tons)
Figure 7. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country/Region (2024)
Figure 10. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Acyclovir API
Figure 12. Product Picture of Zidovudine API
Figure 13. Product Picture of Entecavir API
Figure 14. Product Picture of Sofosbuvir API
Figure 15. Product Picture of Other
Figure 16. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Type in 2025
Figure 17. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Type (2020-2025)
Figure 18. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Consumed in Pharmaceuticals
Figure 19. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market: Pharmaceuticals (2020-2025) & (Tons)
Figure 20. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Consumed in Scientific Research
Figure 21. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market: Scientific Research (2020-2025) & (Tons)
Figure 22. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Market Share by Application (2024)
Figure 23. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Application in 2025
Figure 24. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Company in 2025 (Tons)
Figure 25. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Company in 2025
Figure 26. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Company in 2025 ($ millions)
Figure 27. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Company in 2025
Figure 28. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Geographic Region in 2025
Figure 30. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales 2020-2025 (Tons)
Figure 31. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue 2020-2025 ($ millions)
Figure 32. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales 2020-2025 (Tons)
Figure 33. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue 2020-2025 ($ millions)
Figure 34. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales 2020-2025 (Tons)
Figure 35. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales 2020-2025 (Tons)
Figure 37. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue 2020-2025 ($ millions)
Figure 38. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country in 2025
Figure 39. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Country (2020-2025)
Figure 40. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Type (2020-2025)
Figure 41. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Application (2020-2025)
Figure 42. United States Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Region in 2025
Figure 47. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Region (2020-2025)
Figure 48. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Type (2020-2025)
Figure 49. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Application (2020-2025)
Figure 50. China Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 54. India Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 56. China Taiwan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country in 2025
Figure 58. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Country (2020-2025)
Figure 59. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Type (2020-2025)
Figure 60. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Application (2020-2025)
Figure 61. Germany Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 62. France Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 63. UK Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Type (2020-2025)
Figure 68. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Application (2020-2025)
Figure 69. Egypt Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 72. Turkey Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Nucleoside Antiviral Active Pharmaceutical Ingredient (API) in 2025
Figure 75. Manufacturing Process Analysis of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
Figure 76. Industry Chain Structure of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
Figure 77. Channels of Distribution
Figure 78. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Forecast by Region (2026-2031)
Figure 79. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share Forecast by Region (2026-2031)
Figure 80. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share Forecast by Type (2026-2031)
Figure 81. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share Forecast by Type (2026-2031)
Figure 82. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share Forecast by Application (2026-2031)
Figure 83. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
Figure 2. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Growth Rate 2020-2031 (Tons)
Figure 7. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country/Region (2024)
Figure 10. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Acyclovir API
Figure 12. Product Picture of Zidovudine API
Figure 13. Product Picture of Entecavir API
Figure 14. Product Picture of Sofosbuvir API
Figure 15. Product Picture of Other
Figure 16. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Type in 2025
Figure 17. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Type (2020-2025)
Figure 18. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Consumed in Pharmaceuticals
Figure 19. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market: Pharmaceuticals (2020-2025) & (Tons)
Figure 20. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Consumed in Scientific Research
Figure 21. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market: Scientific Research (2020-2025) & (Tons)
Figure 22. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sale Market Share by Application (2024)
Figure 23. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Application in 2025
Figure 24. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Company in 2025 (Tons)
Figure 25. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Company in 2025
Figure 26. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Company in 2025 ($ millions)
Figure 27. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Company in 2025
Figure 28. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Geographic Region in 2025
Figure 30. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales 2020-2025 (Tons)
Figure 31. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue 2020-2025 ($ millions)
Figure 32. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales 2020-2025 (Tons)
Figure 33. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue 2020-2025 ($ millions)
Figure 34. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales 2020-2025 (Tons)
Figure 35. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales 2020-2025 (Tons)
Figure 37. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue 2020-2025 ($ millions)
Figure 38. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country in 2025
Figure 39. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Country (2020-2025)
Figure 40. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Type (2020-2025)
Figure 41. Americas Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Application (2020-2025)
Figure 42. United States Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Region in 2025
Figure 47. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Region (2020-2025)
Figure 48. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Type (2020-2025)
Figure 49. APAC Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Application (2020-2025)
Figure 50. China Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 54. India Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 56. China Taiwan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country in 2025
Figure 58. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Country (2020-2025)
Figure 59. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Type (2020-2025)
Figure 60. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Application (2020-2025)
Figure 61. Germany Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 62. France Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 63. UK Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Type (2020-2025)
Figure 68. Middle East & Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Application (2020-2025)
Figure 69. Egypt Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 72. Turkey Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Nucleoside Antiviral Active Pharmaceutical Ingredient (API) in 2025
Figure 75. Manufacturing Process Analysis of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
Figure 76. Industry Chain Structure of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
Figure 77. Channels of Distribution
Figure 78. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Forecast by Region (2026-2031)
Figure 79. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share Forecast by Region (2026-2031)
Figure 80. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share Forecast by Type (2026-2031)
Figure 81. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share Forecast by Type (2026-2031)
Figure 82. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share Forecast by Application (2026-2031)
Figure 83. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share Forecast by Application (2026-2031)
